Cystatin C is not a good candidate biomarker for HNF1A-MODY by Nowak, Natalia et al.
SHORT COMMUNICATION
Cystatin C is not a good candidate biomarker for HNF1A-MODY
Natalia Nowak • Magdalena Szopa • Gaya Thanabalasingham • Tim J. McDonald •
Kevin Colclough • Jan Skupien • Timothy J. James • Beata Kiec-Wilk • Elzbieta Kozek •
Wojciech Mlynarski • Andrew T. Hattersley • Katharine R. Owen • Maciej T. Malecki
Received: 3 September 2011 / Accepted: 30 January 2012 / Published online: 19 February 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Cystatin C is a marker of glomerular filtration
rate (GFR). Its level is influenced, among the others, by
CRP whose concentration is decreased in HNF1A-MODY.
We hypothesized that cystatin C level might be altered in
HNF1A-MODY. We aimed to evaluate cystatin C in
HNF1A-MODY both as a diagnostic marker and as a
method of assessing GFR. We initially examined 51
HNF1A-MODY patients, 56 subjects with type 1 diabetes
(T1DM), 39 with type 2 diabetes (T2DM) and 43 non-
diabetic individuals (ND) from Poland. Subjects from two
UK centres were used as replication panels: including 215
HNF1A-MODY, 203 T2DM, 39 HNF4A-MODY, 170
GCK-MODY, 17 HNF1B-MODY and 58 T1DM patients.
The data were analysed with additive models, adjusting for
gender, age, BMI and estimated GFR (creatinine). In the
Polish subjects, adjusted cystatin C level in HNF1A-
MODY was lower compared with T1DM, T2DM and ND
(p \ 0.05). Additionally, cystatin C-based GFR was higher
than that calculated from creatinine level (p \ 0.0001) in
HNF1A-MODY, while the two GFR estimates were similar
or cystatin C-based lower in the other groups. In the UK
subjects, there were no differences in cystatin C between
HNF1A-MODY and the other diabetic subgroups, except
HNF1B-MODY. In UK HNF1A-MODY, cystatin C-based
GFR estimate was higher than the creatinine-based one
(p \ 0.0001). Concluding, we could not confirm our
hypothesis (supported by the Polish results) that cystatin C
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level is altered by HNF1A mutations; thus, it cannot be
used as a biomarker for HNF1A-MODY. In HNF1A-
MODY, the cystatin C-based GFR estimate is higher than
the creatinine-based one.
Keywords Monogenic diabetes  MODY  Cystatin C 
HNF1A
Introduction
Cystatin C is a low-molecular-weight protein produced at a
constant rate in all nucleated cells; it is freely filtered in the
renal glomeruli, reabsorbed and catabolized in the proxi-
mal tubules [1]. Cystatin C has been shown to be an
excellent marker of glomerular filtration rate (GFR) in
healthy individuals and various disease states, including
diabetes [1, 2]. Mutations in HNF1A, encoding hepatocyte
nuclear factor-1alpha, are a common cause of maturity-
onset diabetes of the young (MODY) in Europeans [3], but
not in Asians [4]. This form of diabetes is characterized by
impaired insulin secretion [5]. Making an accurate diag-
nosis of HNF1A-MODY can improve patients’ treatment
[6]. Currently, genetic testing is considered too expensive
to be widely used. The solution may lie in the development
of non-genetic biomarkers that can be used as a more
economical screening test to identify those at highest risk
of MODY prior to molecular testing.
The recently published report described lower hsCRP
levels in HNF1A-MODY [7]. Interestingly, CRP is one of
the factors other than GFR that affect cystatin C levels.
Elevated CRP has been consistently associated with
increased cystatin C [8–10]. Thus, we hypothesized that the
serum cystatin C level may be altered by HNF1A muta-
tions. Additional justification for this study has come from
the fact that the clinical picture of HNF1A-MODY
includes several renal phenotypes, including tubulopathy
with generalized aminoaciduria and glycosuria [11–13].
The aims of the current study were (1) to evaluate cystatin
C as a diagnostic biomarker for HNF1A-MODY and (2) to
assess whether cystatin C provides a reliable estimate of
GFR in subjects with HNF1A-MODY.
Methods
ÌIn an initial study, we included 51 HNF1A-MODY
patients, 56 subjects with type 1 diabetes mellitus (T1DM),
41 with type 2 diabetes mellitus (T2DM) and 43 non-dia-
betic individuals (ND) from Poland. Subjects from two UK
centres were used as replication panels. The Oxford subjects
consisted of 36 HNF1A-MODY cases and 36 young-onset
T2DM (diagnosed B45 years of age) matched for gender,
current age and serum creatinine. The Exeter subjects
consisted of 179 HNF1A-MODY, 167 T2DM, 39 HNF4A-
MODY, 170 GCK-MODY, 17 HNF1B-MODY and 58
T1DM patients. In the UK (Oxford) group, one HNF1A-
MODY subject and 5 T2DM subjects were of non-European
origin. All the other individuals were European Caucasians.
In all three centres, serum creatinine was analysed using
a Jaffe method with calibration aligned to IDMS. In Poland
and Exeter, the measurements were done using the Roche
P800 analyser (Roche Diagnostics, Burgess Hill, UK),
while in Oxford, the ADVIA 2400 device (Siemens
Diagnostics, Frimley, UK) was used. Polish samples were
analysed for cystatin C using a particle-enhanced assay
nephelometric immunoassay (PENIA) with N-Latex cyst-
atin C kit on a BNNII analyser (Dade-Behring, Marburg,
Germany). The UK samples were analysed using particle-
enhanced turbidimetric immunoassay (PETIA) using either
the ADVIA 2400 analyser (Oxford) or the P800 modular
system (Exeter). HsCRP was analysed on the Polish sam-
ples using immunoturbidimetry.
We estimated GFR from creatinine with the CKD-EPI
formula [14] and from cystatin C with the 4-variable formula
[1]. The data were analysed with linear regression models,
with the addition of estimated nonlinear nonparametric
additive components in order to relax the linearity assump-
tion, when adjusting for confounders. p values\0.05 were
considered significant. The statistical analysis was per-
formed with SAS 9.2.
Results
The study groups’ characteristics are shown in Table 1. In
the Polish cohort, we identified 3 HNF1A-MODY patients
with chronic kidney disease (CKD) defined as CKD-EPI
estimated GFR (eGFR) \60 ml/min/1.73 m2 [15]; there
were 5 such individuals in the T1DM group, 6 in the T2DM
group and none in the ND group. Cystatin C level in
HNF1A-MODY was similar to that observed in ND indi-
viduals (p = 0.95) and significantly lower than in the other
diabetic groups (p \ 0.0001 for both groups). Adjusting for
differences in CKD-EPI eGFR, gender, age and BMI
revealed a significantly lower cystatin C level in HNF1A-
MODY compared with T1DM, T2DM and ND groups
(0.197 mg/l less than T1DM, 95% CI: 0.138–0.257,
p \ 0.0001; 0.148 mg/l less than T2DM, 95% CI:
0.083–0.214, p \ 0.0001; and 0.069 mg/l less than ND,
95% CI: 0.06–0.133, p \ 0.03). With adjustment for eGFR
only and with adjustment to HbA1c among diabetic groups,
the pattern of mean cystatin C levels and statistical sig-
nificance of differences remained unchanged.
Using a linear model, instead of additive as the sensi-
tivity analysis, did not change the conclusions or statistical
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significance, nor did exclusion of subjects with CKD. To
further investigate the observed reduced cystatin C levels
in HNF1A-MODY, we compared the patients’ GFR esti-
mated with the CKD-EPI formula with the GFR estimated
from cystatin C (Table 1). The crude differences between
creatinine and cystatin C-based estimated GFRs were not
significant in ND individuals (the CKD-EPI GFR estimate
was 1.4 ml/min/1.73 m2 less, 95% CI: -7.3–4.6), nor in
T2DM (the CKD-EPI estimate was 2.0 ml/min/1.73 m2
higher, 95% CI: -4.2–8.3). In T1DM, the CKD-EPI esti-
mate was 12.5 ml/min/1.73 m2 higher (95% CI: 7.3–17.7,
p \ 0.0001), while in the HNF1A-MODY group the dif-
ference was in the opposite direction: the CKD-EPI esti-
mate was 13.8 ml/min/1.73 m2 less than cystatin C-based
GFR (95% CI: 8.3–19.3, p \ 0.0001). These results were
not altered by adjusting for possible confounders.
Concordant with recent publications [7], HNF1A-
MODY subjects had substantially lower hsCRP levels
compared with other diabetes subtypes, but also to non-
diabetic individuals (p \ 0.0001, for all pairwise compar-
isons). CRP was a significant predictor of cystatin C
concentration (p \ 0.0001). The pattern of differences in
creatinine and cystatin C GFR estimates was in line with
the pattern of mean serum CRP concentrations measured in
the groups. Specifically, in the groups with the highest
(T1DM) and the lowest (HNF1A-MODY) CRP values, we
observed, respectively, a reduced and an increased cystatin
C-based GFR estimate, as compared with creatinine-based
CKD-EPI estimates.
We subsequently attempted to replicate these findings in
the UK subjects. We observed no differences between
cystatin C concentrations in HNF1A-MODY and T2DM
patients from Oxford (p = 0.8), either before or after
adjusting for covariates (as in Polish cohort). In both
Oxford subject groups, we observed similar large differ-
ences between cystatin C-based and creatinine-based GFR
estimates: the cystatin C-based measure was 27.4 ml/min/
1.73 m2 (95% CI: 19.9–34.9; p \ 0.0001) higher in
HNF1A-MODY and 25.8 ml/min/1.73 m2 (95% CI:
18.2–33.3; p \ 0.0001) higher in T2DM.
In the Exeter subjects, there were no significant differences
in cystatin C (adjusting for CKD-EPI eGFR, sex, age and
BMI) between HNF1A-MODY and T1DM (p = 0.3), T2DM
(p = 0.1), GCK-MODY (p = 0.4) and HNF4A-MODY
(p = 0.9). The HNF1B-MODY subjects had significantly
higher cystatin C, by 0.333 mg/l (95% CI: 0.178–0.488),
compared with HNF1A-MODY (p \ 0.0001). In the
HNF1A-MODY group, the cystatin C-based GFR estimate
was higher than the creatinine-based one by 5.3 ml/min/
1.73 m2 (95% CI: 1.6–9.1, p = 0.005). Thus, this finding was
consistent in all three HNF1A-MODY groups. A higher
cystatin C-based GFR estimate was also observed in the
T1DM subjects recruited through Exeter; the differenceT
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between GFR estimates was 9.6 ml/min/1.73 m2 (95% CI:
3.1–16.2, p = 0.004). There was no statistically significant
difference in the GFR estimates in the HNF4A-MODY
(p = 0.5), GCK-MODY (p = 0.5) and T2DM (p = 0.8)
groups, while in the HNF1B-MODY subjects, the cystatin
C-based GFR estimate was lower (p = 0.0009), consistent
with the significantly higher cystatin C concentration
observed in this subgroup.
Discussion
Our initial results from the Polish population showed that
cystatin C concentration in HNF1A-MODY was reduced
by approximately 10% compared with the non-diabetic
individuals. This is in contrast to the increased cystatin C
level previously reported in common forms of diabetes [8]
and observed in the Polish subjects in this study.
The current research was initially driven by the report
on the decreased CRP level, an important regular of cyst-
atin C level [7], and evidence of abnormalities of renal
tubular function in HNF1A-MODY subjects and a Fan-
coni’s syndrome in an animal model [11, 12, 16]. We
considered that in HNF1A-MODY, lower cystatin C levels
in the Polish cohort could be, at least partially, mediated by
reduced CRP levels. The reduction in cystatin C in these
subjects would translate into overestimated GFR compared
with creatinine-based estimates.
In the UK replication study, we did not observe a dif-
ference in cystatin C levels between the UK HNF1A-
MODY and other diabetes types, except HNF1B-MODY.
Those with HNF1B mutations have predominantly devel-
opmental renal anomalies and renal dysfunction; however,
as the results were adjusted for GFR, this does not fully
explain the difference. This observation warrants further
confirmation. The reason for the heterogeneity between the
results from the Polish and UK centres is unclear; one
possible explanation is a random variation and false posi-
tive result in the initial group. Different cystatin C assays
used at the different sites may have contributed [17], but
this is more likely to have resulted in between-site bias
rather than the observed between-group differences. Dif-
ferences in recruitment procedures and study group char-
acteristics also cannot be ruled out. Whilst there are known
limitations in calculation protocols for estimating GFR
[18], the consistent observation in all three HNF1A-MODY
groups was that GFR calculated using a cystatin C-based
formula was higher than those based on creatinine. This
should be taken into account in the clinical management of
HNF1A-MODY patients. The important strength of this
study is the large HNF1A-MODY sample size and attempt
to replicate in independent cohorts. The shortcoming is the
fact that MODY subjects were compared to relatively small
groups of patients with T1DM and T2DM who differed in
terms of some clinical features. On the other hand, the
statistical analysis chosen in this paper should have
adjusted for these differences, some of which, such as age
of onset and BMI, inevitably associated with the clinical
picture of examined types of diabetes.
In summary, we were not able to confirm our hypothesis
(supported by the results from the Polish subjects) that
cystatin C level is altered by HNF1A mutations; thus, this
molecule cannot be considered a candidate biomarker for
HNF1A-MODY. Additionally, in this form of diabetes, the
cystatin C-based GFR estimate is higher than the creati-
nine-based one.
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